Description of Collaborative Activity: |
Subsequent to the filing of a New Drug Application by a pharmaceutical company, the FDA prepares an “8-factor analysis” of abuse liability and prepares a draft scheduling recommendation. NIDA reviews the draft documents and provides advice regarding potential revisions. |